Why the study?
Does hemodialysis and ultrafiltration reduce plasma concentrations of IR-ANP in patients with end-stage renal disease?
Does hemodialysis and ultrafiltration reduce plasma concentrations of IR-ANP in patients with end-stage renal disease?
Answers are grounded in this paper and cite their sources.
Plasma concentrations of IR-ANP significantly decrease after hemodialysis and ultrafiltration in patients with end-stage renal disease, correlating with blood pressure and supporting volume-dependent secretion.
Plasma concentrations of immunoreactive (IR)-atrial natriuretic polypeptide (ANP) were measured before and after hemodialysis (HD) as well as isolated ultrafiltration (UF) in 9 patients with end-stage renal disease. There were significant falls in plasma concentrations of IR-ANP during both UF (from 78.6 +/- 109.7 to 45.4 +/- 56.8 pg/ml; mean +/- SD; p less than 0.025) and HDs (from 84.7 +/- 48.6 to 35.0 +/- 28.4 (p less than 0.01) on first HD; from 73.7 +/- 74.2 to 31.8 +/- 21.8 pg/ml (p less than 0.01) on later HD). There were distinct positive correlations between blood pressures and plasma concentrations of IR-ANP. These results support the view that ANP is secreted mainly by the expansion of blood volume. The fall in plasma concentrations of IR-ANP after HD seems to be caused by the decrease of blood volume, but not by removal due to dialysis of the peptide. However, the physiological role of ANP in patients with end-stage renal disease remains unknown.
No takes yet. Share an insight, caveat, or question.
Kojima et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: